Antibe Therapeutics Inc.
ATBPFOTCHealthcare
$0.22
$-0.00(-0.19%)
Market Cap$11428827
P/E Ratio—
52W High$0.216
52W Low$0.1889
Antibe Therapeutics Inc. (ATBPF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ATBPF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-03 | 2022-03 | 2021-03 | 2020-03 | 2019-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| Cost of Revenue | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| Gross Profit | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | 36.55% | 38.24% | 37.22% |
| Operating Expenses | |||||
| R&D Expenses | $0.01B | $0.01B | $0.02B | $0.01B | $0.00B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.02B | $0.03B | $0.02B | $0.02B | $0.02B |
| Operating Income | ($0.02B) | ($0.03B) | ($0.02B) | ($0.02B) | ($0.01B) |
| Operating Margin %(computed) | — | — | -242.26% | -192.61% | -127.77% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.02B) | ($0.03B) | ($0.02B) | ($0.02B) | ($0.01B) |
| Income Tax Expense | $0.00B | ($0.00B) | $0.00B | ($0.00B) | $0.00B |
| Net Income | ($0.02B) | ($0.03B) | ($0.03B) | ($0.02B) | ($0.01B) |
| Net Margin %(computed) | — | — | -270.78% | -200.11% | -134.35% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.37 | $-0.49 | $-0.70 | $-0.71 | $-0.60 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.04B | 0.03B | 0.02B |
| EBITDA | ($0.02B) | ($0.03B) | ($0.02B) | ($0.02B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | -236.87% | -186.00% | -124.07% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · B
Explore more Antibe Therapeutics Inc. data
About Antibe Therapeutics Inc. (ATBPF) Income Statement
Antibe Therapeutics Inc. (ATBPF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, ATBPF reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.02B) — a net profit margin of —.
Frequently asked questions
ATBPF · 4 questionsAntibe Therapeutics Inc. (ATBPF) reported revenue of $0.00B for 2023, down —% year-over-year.
ATBPF revenueATBPF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09